Home / Research Library / Comparisons
The BPC-157 vs TB-500 question compares two unrelated peptides. BPC-157 is a 15-residue fragment of a protein its developers isolated from gastric juice; TB-500 is a synthetic, N-acetylated seven-residue fragment of thymosin beta-4 (Ac-LKKTETQ). Both have been studied mainly in cell and animal models of tissue repair, neither has published controlled human trials, and both are Schedule 4 substances in Australia and prohibited in sport.1,2,3,4,5,6
They tend to be discussed together because both are linked, in laboratory models, to cell migration and the formation of new blood vessels. This comparison sets out how they actually differ: structure, reported mechanisms, strength of evidence and regulatory status.
| Property | BPC-157 | TB-500 |
|---|---|---|
| Parent molecule | BPC, a gastric juice protein of about 40,000 Da described in 1993 | Thymosin beta-4 (Tβ4), a 43-residue actin-binding peptide |
| Length | 15 amino acids | 7 amino acids, N-terminally acetylated |
| Sequence (one-letter) | GEPPPGKPADDAGLV | Ac-LKKTETQ |
| Molecular formula (PubChem) | C62H98N16O22 | C38H68N10O14 |
| Molar mass (PubChem) | 1419.5 g/mol | 889.0 g/mol |
| CAS number | 137525-51-0 | 885340-08-9 |
| Main reported pathways (lab models) | VEGFR2–Akt–eNOS; FAK–paxillin | Actin binding through the LKKTETQ motif |
| Main evidence base | Rodent and cell studies; three small uncontrolled human reports | Cell and ex vivo assays for the fragment; most data are for full-length Tβ4 |
| Published controlled human trials | None | None for the fragment |
| Poisons Standard (June 2026) | Schedule 4; Appendix D, clause 5 | Schedule 4; Appendix D, clause 5 |
| WADA Prohibited List 2026 | S0, non-approved substances | S2.3, as a derivative of thymosin-β4 |
Formula, mass and CAS values are from PubChem; regulatory entries are from the instruments linked below.5,6,7
BPC-157 was introduced in 1993 by researchers at the University of Zagreb as a 15-amino-acid fragment of "BPC", a gastric juice protein of about 40,000 Da that they proposed as a mediator of an organ-protective stress response.1 Their overview framed the peptide as a possible prototype of a new class of "organoprotective" drugs, on the basis of animal studies.1
TB-500 has a different lineage. It derives from thymosin beta-4, a naturally occurring 43-residue peptide regarded as the main G-actin-sequestering molecule in mammalian cells.8 Doping-control laboratories identified the active ingredient of products sold as TB-500 as Tβ4 residues 17–23 with an added N-terminal acetyl group, the region of Tβ4 responsible for actin binding.2,9 The human trials in this literature used the full-length protein rather than the fragment, and the FDA says it has identified no human exposure data for the fragment itself;4,10 our TB-500 and thymosin beta-4 overview explains why that distinction matters.
A 2017 mechanistic study reported that BPC-157 increased expression and internalisation of the VEGF receptor VEGFR2 in human endothelial cells and activated VEGFR2–Akt–eNOS signalling, with pro-angiogenic effects in chick embryo membrane assays and a rat hind-limb ischaemia model.11 In rat tendon fibroblasts, BPC-157 increased migration, spreading and survival under oxidative stress, but not proliferation, with dose-dependent phosphorylation of FAK and paxillin, two proteins involved in cell adhesion.12
For TB-500, the proposed mechanism is structural. LKKTETQ is the part of Tβ4 that binds actin, and in a 2003 study the seven-residue motif on its own matched full-length Tβ4 in endothelial cell migration and aortic-ring sprouting assays, while peptides missing any part of the motif were inactive.8 Signalling effects reported in studies of the whole protein cannot simply be assumed for the fragment, which lacks the other active regions of Tβ4.
So the overlap between the two is in the outcomes measured in laboratory assays (cell migration, new vessel formation), not in structure or molecular target. Two compounds that both raise a vessel count in an egg membrane assay are not thereby doing the same thing.
| Evidence level | BPC-157 | TB-500 (fragment) | Tβ4 (full length) |
|---|---|---|---|
| In vitro / ex vivo | Tendon fibroblasts, endothelial cells | Endothelial migration, aortic sprouting | Extensive |
| Animal | Extensive, mostly rat | A horse administration study for doping detection | Extensive, including rodent wound and cardiac models |
| Human | Three uncontrolled pilot reports (2 to 16 participants) | No human exposure data identified by the FDA | Phase I and phase II trials |
Each rung of that ladder filters out findings that looked promising on the rung below. Cell and animal studies generate hypotheses; early human trials test safety and how the body handles a compound; only randomised, controlled and adequately sized trials can show whether an effect seen in animals exists in people. For BPC-157 the ladder stops at uncontrolled pilot reports. For the TB-500 fragment it stops before any documented human exposure. Full-length Tβ4 has reached controlled phase I and phase II trials, but those results belong to a different molecule.
BPC-157. A 2025 systematic review included 36 studies, of which 35 were preclinical and one was clinical.3 The published human reports, a retrospective knee-pain chart review, a single-arm interstitial cystitis study and a two-person intravenous safety study, had no control groups, and a 2025 review noted that all published BPC-157 studies report positive effects, raising the possibility of publication bias.13,14
TB-500. Here the evidence problem is different. The human data that exist for this peptide family come from full-length Tβ4, including a phase I intravenous safety trial in healthy volunteers.10 For the fragment itself, the FDA states that it "has not identified any human exposure data" for drug products containing it.4
A 2026 primer for orthopaedic and sports medicine physicians summarised both: BPC-157's tendon and muscle findings are "largely unvalidated in human trials", and Tβ4 and TB-500 "promoted angiogenesis and tissue repair in preclinical models, but human orthopaedic data are lacking".15
Searches for "BPC-157 and TB-500" are common, but the published evidence on the two together is almost non-existent. In PubMed searches for this article (September 2026) we found no controlled study, in animals or humans, of the two in combination. The only published report is the 2021 retrospective knee-pain chart review, in which four of 16 patients had received BPC-157 together with a peptide the authors describe as thymosin-beta-4 (TB4); three of those four reported improvement, with no control group and no validated outcome measures.13 That cannot show an effect of either peptide, let alone an interaction between them.
Showing that two compounds interact needs a specific design: groups receiving each compound alone, both together and a placebo, with enough subjects to detect a difference between the combination and each single agent. Without that factorial structure, any result for the pair cannot be attributed to the pair rather than to one component, or to neither. No published study of BPC-157 and TB-500 has used it.
For researchers, the most practical differences are identity and handling. The two peptides differ in mass by about 530 g/mol (1419.5 versus 889.0 g/mol), so mass spectrometry distinguishes them easily. For TB-500, documentation should also confirm the N-terminal acetyl group, which the Hong Kong laboratory describes as artificial: within natural Tβ4, leucine 17 is joined to the preceding residue, not acetylated.7,9 Their compositions differ too. BPC-157 has a free N-terminus, four prolines, three acidic residues (one glutamate, two aspartates) and one lysine, so it carries a net negative charge at neutral pH. Ac-LKKTETQ has two lysines, one glutamate and a blocked N-terminus, which leaves it close to neutral. Differences like these affect how each behaves in ion-exchange and reversed-phase methods, so analytical conditions developed for one should not be assumed to suit the other.
Naming is a further trap. "TB-500" is a product name rather than an official nonproprietary name, and the analytical studies that pinned it to Ac-LKKTETQ did so by testing what was actually in a product.2,9 The same logic applies to any sample of either peptide: the documented sequence and an observed mass that matches it define what is in the vial, not the name on the label.
Both are handled as lyophilised powders, so general guidance on storing lyophilised and reconstituted peptides applies to each. Titan Peptides supplies BPC-157 and TB-500 for laboratory research only, and the BPC-157 research overview covers that peptide's literature in more depth.
Much of what circulates about these two peptides compares them loosely, or blends their literatures together. Five questions help separate evidence from assertion:
Because the two compounds are unrelated, the relevant background reading depends on the question rather than on which peptide is more popular:
They are unrelated peptides. BPC-157 is a 15-amino-acid fragment (GEPPPGKPADDAGLV) of a protein described in human gastric juice. TB-500 is a synthetic, N-acetylated seven-residue fragment of thymosin beta-4 (Ac-LKKTETQ). They differ in origin, size, sequence and proposed mechanism, and overlap only in some outcomes measured in laboratory assays.
The evidence cannot answer that. No study has compared the two head to head, neither has published controlled human trials of its own, and they are different molecules with different proposed mechanisms. The more useful question for a researcher is which body of literature is relevant to the specific question being studied.
Barely. In PubMed searches in September 2026 we found no controlled animal or human study of the two in combination. The only published report is a 2021 retrospective chart review in which four patients received BPC-157 with a peptide described as thymosin beta-4, with no control group, which cannot show any effect.
Both are listed in Schedule 4, prescription-only medicines, of the June 2026 Poisons Standard, and both appear in Appendix D, clause 5, which covers poisons that must not be possessed without authority such as a legal prescription. Thymosin beta 4 has its own identical listing. States and territories implement scheduling through their own legislation.
Yes. The 2026 WADA Prohibited List names BPC-157 in class S0, non-approved substances, and lists thymosin-β4 and its derivatives, naming TB-500, in class S2.3, growth factors and growth factor modulators. Substances in both classes are prohibited at all times, in and out of competition.
A plain-English review of the BPC-157 literature: where the peptide came from, what animal and cell studies reported, why human evidence is so thin, and where it sits under Australian scheduling and anti-doping rules.
TB-500 and thymosin beta-4 are not the same molecule. This overview explains the fragment, the full-length protein most studies used, the thin human data, and the Australian and WADA position.
What the TGA, the June 2026 Poisons Standard, the Therapeutic Goods Act and customs law actually say about peptides, "research use only" labels, importing and advertising in Australia.
